Belimumab, approved for treatment of SLE, is a human monoclonal antibody targeting B-cell activating factor (BAFF), a TNF-like cytokine involved in B-cell survival and differentiation. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.